Liminatus Pharma (LIMN) Short Interest Ratio & Short Volume

Short interest is the volume of Liminatus Pharma shares that have been sold short but have not yet been closed out or covered. As of August 31st, traders have sold 311,800 shares of LIMN short. 5.61% of Liminatus Pharma's shares are currently sold short. Learn More on Liminatus Pharma's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.61% of Liminatus Pharma's floating shares are currently sold short.

Liminatus Pharma saw a increase in short interest in August. As of August 31st, there was short interest totaling 311,800 shares, an increase of 13.9% from the previous total of 273,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Liminatus Pharma currently has issued a total of 26,010,000 shares. Some of Liminatus Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Liminatus Pharma currently has a public float of 5,560,000 shares.

5.61% of Liminatus Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Liminatus Pharma: GENFIT S.A. Unsponsored ADR (0.06%), Tiziana Life Sciences Ltd (1.25%), MediWound Ltd. (11.71%), Entrada Therapeutics, Inc. (4.81%), SELLAS Life Sciences Group, Inc. (28.26%), Heron Therapeutics, Inc. (22.44%), Eupraxia Pharmaceuticals Inc. (0.66%), Journey Medical Corporation (15.14%), Innate Pharma S.A. Sponsored ADR (0.08%), C4 Therapeutics, Inc. (5.82%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($73.23 billion), Invesco QQQ ($29.52 billion), iShares Russell 2000 ETF ($20.82 billion), iShares 20+ Year Treasury Bond ETF ($10.76 billion), Palo Alto Networks, Inc. ($9.37 billion), Strategy Inc ($7.58 billion), Invesco S&P 500 Equal Weight ETF ($6.78 billion), SPDR S&P Biotech ETF ($6.72 billion), AppLovin Corporation ($6.37 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($6.29 billion). View all of the most shorted stocks.

Short selling LIMN is an investing strategy that aims to generate trading profit from Liminatus Pharma as its price is falling. LIMN shares are trading down $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Liminatus Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of LIMN, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LIMN, twice per month. The most recent reporting period available is August, 31 2025.